2
Clinical Trials associated with FHND1002 / Not yet recruitingPhase 1 一项评价FHND1002颗粒在健康成年志愿者中单/多次给药的安全性、耐受性和药代动力学特征的I期临床研究
[Translation] A Phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of single/multiple administrations of FHND1002 granules in healthy adult volunteers
主要目的:评估FHND1002颗粒在健康成年志愿者中单/多次给药后的安全性和耐受性。次要目的:1)评估FHND1002颗粒在健康成年志愿者中的药代动力学(PK)特征;2)初步开展人体中药物代谢产物的研究。
[Translation] Primary objective: To evaluate the safety and tolerability of FHND1002 granules after single/multiple administration in healthy adult volunteers. Secondary objectives: 1) To evaluate the pharmacokinetic (PK) characteristics of FHND1002 granules in healthy adult volunteers; 2) To conduct preliminary studies on drug metabolites in humans.
/ Enrolling by invitationPhase 1 A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of FHND1002 Granules After Single and Multiple Doses in Healthy Adult Volunteers
The goal of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of FHND1002 granules in healthy adult volunteers. The study will also assess how a high-fat meal affects the PK characteristics of FHND1002.
The main questions this study aims to answer are:
What are the safety and tolerability of FHND1002 granules when administered as single or multiple doses? What are the PK parameters of FHND1002, and what metabolites can be identified in humans?
Participants will:
Take FHND1002 granules or a placebo once daily, either as a single dose or for 7 consecutive days.
Attend regular clinic visits for checkups, tests, and blood sample collection. Undergo assessments, including monitoring for adverse events, physical exams, vital signs, ECGs, and laboratory tests.
100 Clinical Results associated with FHND1002
100 Translational Medicine associated with FHND1002
100 Patents (Medical) associated with FHND1002
100 Deals associated with FHND1002